TG Therapeutics | TGTX - Assets


TG Therapeutics reported $1.06B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Alaunos Therapeutics USD 2.97M 758K Dec/2025
Amgen USD 92.5B 1.92B Mar/2026
Ardelyx USD 504.51M 2.9M Mar/2026
Arrowhead Research USD 1.6B 218.89M Dec/2025
Bayer EUR 104.54B 331M Dec/2025
Biogen USD 29.48B 43.6M Mar/2026
Corcept Therapeutics USD 814.88M 21.77M Mar/2026
Curis USD 19.97M 9.27M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Infinity Pharmaceuticals USD 21.23M 8.72M Jun/2023
J&J USD 200.89B 1.68B Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Novartis USD 118.53B 7.58B Mar/2026
Novavax USD 1.18B 3.38M Dec/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
TG Therapeutics USD 1.06B 38.23M Dec/2025
Verastem USD 246.44M 69.59M Dec/2025
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026